Type I interferon: Potential therapeutic target for psoriasis?

PLoS ONE

Volumn 3, Issue 7, 2008, Pages

  Yao, Yihong ^a   Richman, Laura ^a   Morehouse, Chris ^a   de los Reyes, Melissa ^a   Higgs, Brandon W ^a   Boutrin, Anmarie ^a   White, Barbara ^a   Coyle, Anthony ^a   Krueger, James ^b   Kiener, Peter A ^a   Jallal, Bahija ^a  

^a Medlmmune Inc   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; INTERFERON; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; CYTOKINE; ISG15 PROTEIN, HUMAN; STAT1 PROTEIN; STAT1 PROTEIN, HUMAN; UBIQUITIN;

ARTICLE; CELL INFILTRATION; CONTROLLED STUDY; DENDRITIC CELL; GENE OVEREXPRESSION; GENOME ANALYSIS; HUMAN; HUMAN CELL; HUMAN TISSUE; KERATINOCYTE; PATHOGENESIS; PROTEIN TARGETING; PSORIASIS; SKIN BIOPSY; SKIN DEFECT; T LYMPHOCYTE; UPREGULATION; BIOLOGICAL MODEL; BIOPSY; CELL DIFFERENTIATION; CLUSTER ANALYSIS; GENE EXPRESSION REGULATION; METABOLISM; PATHOLOGY; SKIN;

BIOPSY; CELL DIFFERENTIATION; CLUSTER ANALYSIS; CYTOKINES; GENE EXPRESSION REGULATION; HUMANS; INTERFERON TYPE I; INTERFERON TYPE II; KERATINOCYTES; MODELS, BIOLOGICAL; PSORIASIS; RNA, MESSENGER; SKIN; STAT1 TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR-ALPHA; UBIQUITINS;

EID: 50549092820     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0002737     Document Type: Article

References (38)

1. Krueger JG (2002) The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 46: 1-23; quiz 23-26.
2. Lebwohl M (2003) Psoriasis. Lancet 361: 1197-1204.
3. Nestle FO, Gilliet M (2005) Defining upstream elements of psoriasis pathogenesis: an emerging role for interferon alpha. J Invest Dermatol 125: xiv-xv.
4. Chamian F, Krueger JG (2004) Psoriasis vulgaris: an interplay of T lymphocytes, dendritic cells, and inflammatory cytokines in pathogenesis. Curr Opin Rheumatol 16: 331-337.
5. Chamian F, Lowes MA, Lin SL, Lee E, Kikuchi T, et al. (2005) Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A 102: 2075-2000.
6. Zhou X, Krueger JG, Kao MC, Lee E, Du F, et al. (2003) Novel mechanisms of T-cell and dendritic cell activation revealed by profiling of psoriasis on the 63,100-element oligonucleotide array. Physiol Genomics 13: 69-78.
7. Lee E, Trepicchio WL, Oestreicher JL, Pittman D, Wang F, et al. (2004) Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris. J Exp Med 199: 125-130.
8. Kauffman CL, Aria N, Toichi E, McCormick TS, Cooper KD, et al. (2004) A phase I study evaluating the safety, pharmacokinetics, and clinical response of a human IL-12 p40 antibody in subjects with plaque psoriasis. J Invest Dermatol 123: 1037-1044.
9. Mee JB, Cork MJ, di Giovine FS, Duff GW, Groves RW (2005) Interleukin-1: A key inflammatory mediator of psoriasis? Cytokine 33: 72-78.
10. Boniface K, Diveu C, Morel F, Pedretti N, Froger J, et al. (2007) Oncostatin M secreted by skin infiltrating T lymphocytes is a potent keratinocyte activator involved in skin inflammation. J Immunol 178: 4615-4622.
11. Zheng Y, Danilenko DM, Valdez P, Kasman I, Eastham-Anderson J, et al. (2007) Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 445: 640-651.
12. Lew W, Bowcock AM, Krueger JG (2004) Psoriasis vulgaris: cutaneous lymphoid tissue supports T-cell activation and "Type 1" inflammatory gene expression. Trends Immunol 25: 295-305.
13. Data on File. MedImmune, Gaithersburg, MD.
14. Livden JK, Nilsen R, Bjerke JR, Matre R (1989) In situ localization of interferons in psoriatic lesions. Arch Dermatol Res 281: 392-397.
15. Schmid P, Itin P, Cox D, McMaster GK, Horisberger MA (1994) The type I interferon system is locally activated in psoriatic lesions. J Interferon Res 14: 229-234.
16. Cella M, Jarrossay D, Facchetti F, Alebardi O, Nakajima H, et al. (1999) Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med 5: 919-923.
17. Siegal FP, Kadowaki N, Shodell M, Firzgerald-Bocarsly PA, Shah K, et al. (1999) The nature of the principal type 1 interferon-producing cells in human blood. Science 234: 1835-1837.
18. Eriksen KW, Lovato P, Skov L, Krejsgaard T, Kaltoft K, et al. (2005) Increased sensitivity to interferon-alpha in psoriatic T cells. J Invest Dermatol 125: 936-944.
19. van der Fits L, van der Wel LI, Laman JD, Prens EP, Verschuren MC (2004) In psoriasis lesional skin the type I inrerferon signaling pathway is activated, whereas interferon-alpha sensitivity is unaltered. J Invest Dermatol 122: 51-60.
20. Downs AM, Dunnill MG (2000) Exacerbation of psoriasis by interferon-alpha therapy for hepatitis C. Clin Exp Dermatol 25: 351-352.
21. Funk J, Langeland T, Schrumpf E, Hanssen LE (1991) Psoriasis induced by interferon-alpha. Br J Dermatol 125: 463-465.
22. Ketikoglou I, Karatapanis S, Elefsiniotis I, Kafiri G, Moulakakis A (2005) Extensive psoriasis induced by pegylated interferon alpha-2b treatment for chronic hepatitis B. Eur J Dermatol 15: 107-109.
23. Pauluzzi P, Kokelj F, Perkan V, Pozzato G, Moretti M (1993) Psoriasis exacerbation induced by interferon-alpha. Report of two cases. Acta Derm Venereol 73: 395.
24. Gilliet M, Conrad C, Geiges M, Cozzio A, Thurlimann W, et al. (2004) Psoriasis triggered by toll-like receptor 7 agonist imiquimod in the presence of dermal plasmacytoid dendritic cell precursors. Arch Dermatol 140: 1490-1495.
25. Hida S, Ogasawara K, Sato K, Abe M, Takayanagi H, et al. (2000) CD8(+) T cell-mediated skin disease in mice lacking IRF-2, the transcriptional attenuator of interferon-alpha/beta signaling. Immunity 13: 643-655.
26. Nestle FO, Conrad C, Tun-Kyi A, Homey B, Gombert M, et al. (2005) Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 202: 135-143.
27. Nomura I, Gao B, Boguniewicz M, Darst MA, Travers JB, et al. (2003) Distinct patterns of gene expression in the skin lesions of atopic dermatitis and psoriasis: a gene microarray analysis. J Allergy Clin Immunol 112: 1195-1202.
28. Taniguchi T, Ogasawara K, Takaoka A, Tanaka N (2001) IRF family of transcription factors as regulators of host defense. Annu Rev Immunol 19: 623-655.
29. Au WC, Yeow WS, Pitha PM (2001) Analysis of functional domains of interferon regulatory factor 7 and its association with IRF-3. Virology 280: 273-282.
30. Honda K, Yanai H, Negishi H, Asagiri M, Sato M, et al. (2005) IRF-7 is the master regulator of type-I interferon-dependent immune responses. Nature 434: 772-777.
31. Harada H, Willison K, Sakakibara J, Miyamoto M, Fujita T, et al. (1990) Absence of the type I IFN system in EC cells: transcriptional activator (IRF-1) and repressor (IRF-2) genes are developmentally regulated. Cell 63: 303-312.
32. Zhao C, Denison C, Huibregtse JM, Gygi S, Krug RM (2005) Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc Natl Acad Sci U S A 102: 10200-10205.
33. Christensen SR, Shlomchik MJ (2007) Regulation of lupus-related autoantibody production and clinical disease by Toll-like receptors. Semin Immunol 19: 11-23.
34. Bave U, Nordmark G, Lovgren T, Ronnelid J, Cajander S, et al. (2005) Activation of the type I interferon system in primary Sjogren's syndrome: a possible etiopathogenic mechanism. Arthritis Rheum 52: 1185-1195.
35. Greenberg SA, Pinkus JL, Pinkus GS, Burleson T, Sanoudou D, et al. (2005) Interferon-alpha/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 57: 664-678.
36. Theofilopoulos AN, Baccala R, Beutler B, Kono DH (2005) Type I interferons (alpha/beta) in immunity and autoimmunity. Annu Rev Immunol 23: 307-336.
37. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, et al. (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 100: 2610-2615.
38. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, et al. (2003) Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 197: 711-723.